Helper Virus Is Present Patents (Class 435/457)
-
Patent number: 6620618Abstract: An adenovirus vector/packaging cell line system is disclosed, in which the vector replication is blocked by deletion of a single gene, which deletion does not interfere with any other viral functions. The deleted gene is the gene of the adenovirus protease. The protease is expressed in a complementing (packaging) cell line through a regulatable expression cassette which induces no toxic effects in the cells, thus making the generation and propagation of the vector easier and more efficient. As the deleted gene is highly specific of adenovirus, no complementation of the gene in transduced cells is expected, which increases the safety of the new vectors for gene transfer purposes. Also disclosed is a new system of generating recombinant adenovirus vectors by positive selection of recombinants deleted for the endogenous protease gene, which gene is cloned in another region of the adenoviral genome.Type: GrantFiled: March 30, 2001Date of Patent: September 16, 2003Assignee: National Research Council of CanadaInventors: Bernard Massie, Wahiba Oualikene
-
Patent number: 6613569Abstract: Novel packaging cell lines for production of lentiviral vectors are disclosed. The cell lines utilize an ecdysone-inducible system for virus production, thereby avoiding the cytotoxic effect of unregulated expression of certain envelope proteins and lentiviral proteins. Various embodiments of the cell lines are disclosed, which are suitable for different purposes that range from in vitro screening assays to gene therapy in vivo.Type: GrantFiled: March 5, 2002Date of Patent: September 2, 2003Assignee: University of Medicine and Dentistry of New JerseyInventors: Joseph P Dougherty, Martin E Adelson, Malvika Kaul, AnnMarie L Pacchia, Yacov Ron
-
Patent number: 6596535Abstract: Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.Type: GrantFiled: August 8, 2000Date of Patent: July 22, 2003Assignee: Targeted Genetics CorporationInventor: Barrie J. Carter
-
Patent number: 6596539Abstract: The invention relates to a method and compositions for modifying a phenotype of a virus, such as viral tropism and host range, by iterative sequence recombination of variant viruses and selection of improved variants.Type: GrantFiled: October 30, 1998Date of Patent: July 22, 2003Assignee: Maxygen, Inc.Inventors: Willem P. C. Stemmer, Phillip Patten, Nay Wei Soong
-
Patent number: 6585968Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.Type: GrantFiled: July 2, 2001Date of Patent: July 1, 2003Assignee: Cell Genesys, Inc.Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
-
Publication number: 20030118554Abstract: This invention provides helper-dependent adenovirus cloning vectors and helper adenoviruses, and methods for making and Using such preparations, wherein the helper adenoviruses contain recombinase target sites that are useful in reducing the level of contamination of helper virus in helper-dependent adenovirus vector preparations.Type: ApplicationFiled: July 26, 2002Publication date: June 26, 2003Inventors: Frank Graham, Michael A. Rudnicki, Martina Anton
-
Patent number: 6582691Abstract: The invention relates to an insect cell vector for the production of proteins from the DEAD protein family.Type: GrantFiled: September 29, 2000Date of Patent: June 24, 2003Assignee: Aventis Research & Technologies GmbH & Co.Inventors: Karl-Christian Gallert, Stefan Müllner, Christoph Hüls, Britta Böhnisch
-
Patent number: 6576463Abstract: The invention discloses hybrid vectors for delivering genes or other nucleic acids into mammalian cells. The hybrid vectors of the invention contain both a helper dependent adenoviral portion and a second portion derived from either a replication incompetent retrovirus or from a transposon. Such vectors provide efficient transduction of quiescent cells and provide for stable integration of the gene to be delivered.Type: GrantFiled: January 18, 2000Date of Patent: June 10, 2003Assignee: The Regents of the University of CaliforniaInventors: Noriyuki Kasahara, Collin Higo, Harris Soifer, Kohnosuke Mitani
-
Publication number: 20030104355Abstract: The present invention provides adapter-directed display systems for expressing exogenous polypeptide within a host cell and/or displaying the exogenous polypeptide on the outer surface of a genetic package. This subject systems are particularly useful for displaying a genetically diverse repertoire of monomeric and multimeric polypeptides. The invention also provides both expression and helper vectors and kits containing components of the subject display systems. Also provided are genetic packages displaying the exogenous polypeptides of particular interest. Further provided by the invention are methods of using the subject display systems.Type: ApplicationFiled: November 2, 2001Publication date: June 5, 2003Inventors: Caili Wang, Pingyu Zhong, Xinwei Wang
-
Patent number: 6555107Abstract: The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.Type: GrantFiled: April 17, 2001Date of Patent: April 29, 2003Assignee: The Regents of the University of CaliforniaInventors: Eric M. Poeschla, David J. Looney, Flossie Wong-Staal
-
Patent number: 6555342Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: GrantFiled: December 14, 1999Date of Patent: April 29, 2003Assignee: UAB Research FoundationInventors: John C. Kappes, Xiaoyun Wu
-
Publication number: 20030053990Abstract: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.Type: ApplicationFiled: July 26, 2002Publication date: March 20, 2003Applicant: University of North Carolina at Chapel HillInventors: Joseph E. Rabinowitz, Richard Jude Samulski, Weidong Xiao
-
Patent number: 6531123Abstract: The present invention contemplates novel lentiviral vectors which exhibit strong promoter activity in human and other cells. Vectors are provided which are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks. The present invention further relates to HIV vaccines and compositions for gene therapy. In particular, the present invention provides attenuated replication-competent HIV vaccines and replication defective HIV vectors.Type: GrantFiled: May 25, 1999Date of Patent: March 11, 2003Inventor: Lung-Ji Chang
-
Publication number: 20030022378Abstract: A helper dependent adenoviral vector system is provided. The subject helper dependent adenoviral vector system is made up of: (1) a “gutless” adenoviral vector that include cis-acting human stuffer DNA that provides for in vivo long term, high level expression of a coding sequence present on the vector; (2) an adenoviral helper vector that is characterized by having an adenoviral genome region flanked by recombinase recognition sites, where the helper vectors further include a non-mammalian endonuclease recognition site positioned outside of the adenoviral genome region; and (3) a mammalian cell that expresses the corresponding recombinase and endonuclease, as well as the adenoviral preterminal and polymerase proteins. Also provided are methods of using the subject systems to produce virions having the subject helper dependent adenoviral vectors encapsulated in an adenoviral capsid. In addition, kits for use in practicing the subject methods are provided.Type: ApplicationFiled: March 25, 2002Publication date: January 30, 2003Inventors: Anja Ehrhardt, Mark A. Kay
-
Publication number: 20030017597Abstract: The invention discloses hybrid vectors for delivering genes or other nucleic acids into mammalian cells. The hybrid vectors of the invention contain both a helper dependent adenoviral portion and a second portion derived from a transposon. Such vectors provide efficient transduction of quiescent cells and provide for stable integration of the gene to be delivered.Type: ApplicationFiled: March 19, 2002Publication date: January 23, 2003Inventors: Noriyuki Kasahara, Collin Higo, Harris Soifer, Kohnosuke Mitani
-
Patent number: 6509150Abstract: The present invention relates to methods and compositions for the production of recombinant Adeno-Associated Viruses (rAAV). In particular, the invention discloses nucleic acid constructs and packaging cells having improved properties for rAAV production, as well as novel methods of titration and characterization of rAAV preparations. The invention also describes novel sequences which promote or increase the packaging of nucleic acids in rAAV, and their use for producing rAAV with high efficiency. The invention can be used for producing or testing high quality rAAV preparations, for biological, preclinical, clinical or pharmaceutical uses.Type: GrantFiled: March 5, 1999Date of Patent: January 21, 2003Assignee: Universite de NantesInventors: Anna Salvetti, Pascale Nony, Gilliane Chadeuf, Philippe Moullier
-
Patent number: 6506604Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and, human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.Type: GrantFiled: September 4, 2001Date of Patent: January 14, 2003Assignee: Cell Genesys, Inc.Inventors: Mitchell H. Finer, Thomas J. Dull, Krisztina M. Zsebo, Keegan Cooke, Deborah A. Farson
-
Patent number: 6489167Abstract: This invention provides a Togavirus-amplified retrovirus vector and a novel method for packaging a retrovirus cassette that contains a heterologous nucleic acid, which is amplified in a packaging cell cytoplasm by a Togavirus vector. The retroviral cassette is packaged into infectious retrovirus particles by retroviral packaging cells. These retroviral particles carrying the retroviral packaging cassette are then used to infect host cells.Type: GrantFiled: July 12, 1999Date of Patent: December 3, 2002Assignee: The Government of the United States as represented by the Secretary of the Department of Human ServicesInventors: Richard Morgan, Jarmo Wahlfors, Kleanthis Xanthopoulos
-
Publication number: 20020177544Abstract: An adenoviral transfer vector for the gene transport of a DNA sequence, which is produced from an adenoviral plasmid which no longer expresses any natural adenoviral proteins and comprisesType: ApplicationFiled: February 19, 1999Publication date: November 28, 2002Applicant: AVENTIS BEHRING GMBHInventors: ANJA HAACK, CHRISTOPH SCHMITT
-
Patent number: 6485720Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.Type: GrantFiled: August 8, 2001Date of Patent: November 26, 2002Assignee: Genzyme CorporationInventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
-
Patent number: 6479290Abstract: The invention concerns adenoviral vectors having the characteristic of containing a region essential for heterologous packaging with respect to the adenoviral genome from which they are derived. The invention also concern a method for making a viral preparation containing said adenoviral vectors, a cell, a pharmaceutical composition or material comprising them and their therapeutic or prophylactic use. Finally, the invention concerns an adenoviral genome of animal origin having attenuated packaging properties with respect tot he native genome from which it is derived.Type: GrantFiled: January 27, 2000Date of Patent: November 12, 2002Assignee: Transgene S. A.Inventors: Majid Mehtali, Monika Lusky, Arend Jan Winter
-
Patent number: 6479279Abstract: The invention relates to a recombinant vector for stable persistence of exogenous DNA in a eukaryotic cell, and the uses of the recombinant vector for long-term stable production of gene product in the host cell, the vector including the minichromosomal maintenance element of papillomavirus.Type: GrantFiled: September 28, 1998Date of Patent: November 12, 2002Assignee: Estonian BiocentreInventor: Mart Ustav
-
Patent number: 6479281Abstract: Vector systems that encode viral proteins that will assemble into an infectious lentivirus particle having a deletion of the lentiviral matrix are described. In one embodiment the vectors encode a lentiviral envelope protein that contains a deletion of the cytoplasmic tail. In a second embodiment a heterologous envelope as compared to the lentivirus is used such as an envelope protein that targets an endocytic compartment.Type: GrantFiled: September 26, 2000Date of Patent: November 12, 2002Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Heinrich Göttlinger, Heide Reil, Anatoly Bukovsky
-
Patent number: 6472204Abstract: A method is disclosed for increasing the efficiency of retroviral mediated gene transfer into viable target cells, which comprises transducing the target cells by infecting the target cells with a replication defective recombinant retrovirus that infects the target cells in an aqueous medium in the presence of (a) a mixture of an effective amount of a first functional material having a retrovirus binding domain that binds said retrovirus, and an effective amount of a second functional material having a target cell binding domain that binds said target cell, or (b) an effective amount of a bifunctional material having both a retroviral binding domain which does not contain the heparin binding domain derived from human fibronectin, and a target cell binding domain, wherein the bifunctional material has a retrovirus binding domain that binds to said retrovirus and a target cell binding domain that binds to the target cell.Type: GrantFiled: March 7, 1997Date of Patent: October 29, 2002Inventors: Kiyozo Asada, Takashi Uemori, Takashi Ueno, Nobuto Koyama, Kimakazu Hasino, Ikunoshin Kato
-
Publication number: 20020155610Abstract: The present invention provides methods and compositions for producing high titer, wild-type-free preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include novel nucleic acids encoding AAV helper functions and AAV helper function vectors. The present invention also includes host cells transfected by the claimed nucleic acids, methods of using the claimed vectors, and rAAV virions produced by such methods.Type: ApplicationFiled: February 11, 2002Publication date: October 24, 2002Applicant: Avigen, Inc.Inventor: Peter Colosi
-
Patent number: 6468524Abstract: The present invention relates to AAV4 vectors for methods of delivering nucleic acids to cells. Specifically, the present invention provides methods of delivering nucleic acids to specific regions and cells of the brain, particularly ependymal cells.Type: GrantFiled: March 22, 2000Date of Patent: October 22, 2002Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: John A. Chiorini, Robert M. Kotin, Beverly Davidson
-
Publication number: 20020151509Abstract: The instant invention provides methods of expressing polynucleotides in the cells of the liver comprising administering viral particles comprising a recombinant AAV vector into a mammal, preferably a human.Type: ApplicationFiled: May 22, 2000Publication date: October 17, 2002Inventors: Richard O. Snyder, Lawrence K. Cohen, Mark A. Kay, Oliver Danos, Arthur R. Thompson
-
Publication number: 20020146392Abstract: This invention provides helper-dependent adenovirus cloning vectors and helper adenoviruses, and methods for making and using such preparations, wherein the helper adenoviruses contain recombinase target sites that are useful in reducing the level of contamination of helper virus in helper-dependent adenovirus vector preparations.Type: ApplicationFiled: July 13, 1999Publication date: October 10, 2002Inventors: FRANK L. GRAHAM, PHILLIP NG, ROBIN PARKS, CINDY BEAUCHAMP
-
Patent number: 6458560Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.Type: GrantFiled: October 8, 1999Date of Patent: October 1, 2002Assignees: Chiron Corporation, Washington UniversityInventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilva Frolov
-
Publication number: 20020136708Abstract: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.Type: ApplicationFiled: June 19, 2001Publication date: September 26, 2002Inventors: Frank L. Graham, Philip Ng, Robin Parks, Silvia Bacchetti, Mauro Anglana
-
Patent number: 6436392Abstract: The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.Type: GrantFiled: March 25, 1999Date of Patent: August 20, 2002Assignee: University of Iowa Research FoundationInventors: John F. Engelhardt, Dongsheng Duan
-
Patent number: 6436394Abstract: Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise and adenoviral gene under control of a transcription regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.Type: GrantFiled: July 11, 2000Date of Patent: August 20, 2002Assignee: Cell Genesys, Inc.Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
-
Patent number: 6432699Abstract: The invention involves viral vectors that can be used to transduce a target cell, i.e., to introduce genetic material into the cell. The targets of interest are eukaryotic cells and particularly human cells. The transduction can be done in vivo or in vitro. More particularly the invention concerns viral vectors that have chimeric envelope proteins and contain the IgG-binding domain of protein A. These vectors when used in conjunction with antibodies targeting a particular cell are particularly useful for gene therapy.Type: GrantFiled: March 28, 1997Date of Patent: August 13, 2002Assignee: New York UniversityInventors: Daniel Meruelo, Kouichi Ohno
-
Patent number: 6428988Abstract: Methods for efficient production of recombinant AAV are described. In one aspect, three vectors are introduced into a host cell. A first vector directs expression of cre recombinase, a second vector contains a promoter, a spacer sequence flanked by loxP sites and rep/cap, and a third vector contains a minigene containing a transgene and regulatory sequences flanked by AAV ITRs. In another aspect, the host cell stably or unducibly expresses cre recombinase and two vectors carrying the other elements of the system are introduced into the host cell.Type: GrantFiled: August 7, 2001Date of Patent: August 6, 2002Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Daniel Phaneuf
-
Patent number: 6428953Abstract: Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.Type: GrantFiled: June 26, 2000Date of Patent: August 6, 2002Assignee: Cell Genesys, Inc.Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
-
Patent number: 6423544Abstract: The invention provides host cells comprising a translation operator sequence (TOP) and packaging elements. Also provided are viral vectors comprising a TOP operably linked to a transgene. Also provided are methods of using these host cells and viral vectors to produce recombinant virions.Type: GrantFiled: June 30, 2000Date of Patent: July 23, 2002Assignee: Chiron CorporationInventor: Stephen F. Hardy
-
Patent number: 6416992Abstract: The present invention provides compositions and methods of producing recombinant AAV (rAAV) virions in large amounts or high titers. Also provided are methods for producing stably transformed host cells capable of producing rAAV virions.Type: GrantFiled: October 13, 1999Date of Patent: July 9, 2002Assignee: Avigen, Inc.Inventor: Stephen Mejza
-
Publication number: 20020086419Abstract: The invention relates to a recombinant vector for stable persistence of erogenous DNA in a eukaryotic host cell, and the uses of the recombinant vector for long-term stable production of a gene product in the host cell, the vector including the minimal origin of replication of papillomavirus and the minichromosomal maintenance element of papillomavirus.Type: ApplicationFiled: September 28, 1998Publication date: July 4, 2002Inventor: MART USTAV
-
Patent number: 6410257Abstract: The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to vital vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.Type: GrantFiled: May 1, 2000Date of Patent: June 25, 2002Assignee: The Johns Hopkins University School of MedicineInventors: Boro Dropulic, Paula Pitha-Rowe
-
Publication number: 20020072120Abstract: Novel helper vectors are provided for complementing defective recombinant viral vectors, characterized in that they are provided with recombination sequences recognized by a recombinase. A complementation cell expressing the recombinase, and a method for preparing recombinant viral vectors as infectious viral particles for transferring and expressing genes of interest in a host organism or cell, are also provided. The invention is particularly suitable for use in gene therapy, especially in humans.Type: ApplicationFiled: August 3, 2001Publication date: June 13, 2002Inventors: Monika Lusky, Majid Mehtali
-
Patent number: 6403370Abstract: This invention encompasses a composition for killing target cells, such as tumor cells. The composition comprises a first and a second adenoviral vector that have complementary function and are mutually dependent on each other for replication in a target cell. One of said adenoviral vectors has a target cell-activated promoter or a functional deletion that controls and limits propagation of the adenoviral vectors in the target cells which directly or indirectly kills the target cells. One of the adenoviral vectors comprises a gene encoding a protein which is expressed in the target cells and can induce anticancer immune responses. The target cells may be hepatoma, breast cancer, melanoma, colon cancer, or prostate cancer cells, for example. The vectors of this invention may also be utilized to treat other diseases such as restenosis, in which case the target cell may be a vascular smooth muscle cell, for example.Type: GrantFiled: February 10, 1997Date of Patent: June 11, 2002Assignee: GenStar Therapeutics CorporationInventors: Ramon Alemany, Xiangming Fang, Wei-Wei Zhang
-
Patent number: 6399385Abstract: A rapid method for modifying a viral capsid or envelope protein with a polyethylene glycol (PEG) is described. Also provided are methods of delivering a molecule using the PEG-modified viruses of the invention. Compositions containing the PEG-modified viruses of the invention, are characterized by improved gene expression, reduced neutralizing antibody and CTL production. Also provided are viral compositions having enhanced physical stability, in which the viruses are lyophilized in a formulation having a 1:1 ratio of sucrose and mannitol are provided.Type: GrantFiled: September 27, 2000Date of Patent: June 4, 2002Assignee: The Trustees of the University of PennsylvaniaInventors: Maria Croyle, James M. Wilson
-
Patent number: 6395519Abstract: Cells capable of at least, in part, complementing adenovirus E2A function of an adenovirus defective in E2A function. Such cells include a nucleic acid encoding adenovirus E2A or a functional part, derivative and/or analogue thereof, integrated into the genome of the cell. Preferably, the cell has E2A nucleic acid derived from a temperature sensitive adenovirus such as adenovirus ts125. Methods for producing an adenovirus particle containing an adenovirus vector with a finctional deletion of E2A are also disclosed. Such a method involves providing a cell as previously described with the functionally deleted adenovirus vector, culturing the cell, and harvesting the virus particle. The functional deletion can comprise a deletion of at least part of the nucleic acid encoding E2A.Type: GrantFiled: April 23, 1999Date of Patent: May 28, 2002Assignee: IntroGene B.V.Inventors: Frits J. Fallaux, Robert C. Hoeben, Abraham Bout, Domenico Valerio, Alex J. van der Eb, Govert Schouten
-
Patent number: 6391632Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as is compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.Type: GrantFiled: October 8, 1999Date of Patent: May 21, 2002Assignees: Chiron Corporation, Washington UniversityInventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
-
Patent number: 6387670Abstract: The invention concerns a method for producing recombinant virus. This method is based on the use of baculovirus for providing the complementary functions. It also concerns constructs used for implementing this method, the producing cells, and the resulting virus.Type: GrantFiled: May 18, 1999Date of Patent: May 14, 2002Assignee: Aventis Pharma, S.A.Inventors: Hélène Leblois-Prehaud, Michel Perricaudet, Emmanuelle Vigne, Patrice Yeh
-
Patent number: 6387368Abstract: The present invention provides a hybrid vector construct which comprises a portion of an adenovirus, 5′ and 3′ ITR sequences from an AAV, and a selected transgene. Other hybrid vectors form a polycation conjugate and incorporate an AAV rep gene in a single particle. These hybrid virus vectors are characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome. Also disclosed is the use of the hybrid vectors to produce large quantities of recombinant AAV.Type: GrantFiled: April 11, 2000Date of Patent: May 14, 2002Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, William M. Kelley, Krishna J. Fisher
-
Publication number: 20020051769Abstract: Gene Delivery Vectors and Their UsesType: ApplicationFiled: April 20, 2001Publication date: May 2, 2002Inventor: Xiaoliu Zhang
-
Publication number: 20020042139Abstract: The invention includes a viral vector method and composition comprising transcomplementary replication incompetent viral vectors, preferably adenoviral vectors, which are cotransformed to a recipient cell. The two vectors complement each other and thus allow viral replication, in a synergistic combination which enhances both gene delivery and gene expression of genetic sequences contained within the vector.Type: ApplicationFiled: May 31, 2001Publication date: April 11, 2002Inventors: James N. Higginbotham, Charles J. Link, William J. Ramsey
-
Publication number: 20020037867Abstract: A method of prolonging gene expression by reducing immune response to a recombinant adeno-associated virus (AAV) bearing a desired gene administered into the muscle of a mammal is described.Type: ApplicationFiled: February 26, 1999Publication date: March 28, 2002Inventors: JAMES M. WILSON, KRISHNA J. FISHER
-
Patent number: 6362000Abstract: The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.Type: GrantFiled: November 5, 1999Date of Patent: March 26, 2002Assignee: University of Alabama Research FoundationInventors: John Christopher Kappes, Xiaoyun Wu